BNP Paribas Financial Markets
LBRX

BNP Paribas Financial Markets’s LB Pharmaceuticals LBRX Stock Holding History

BNP Paribas Financial Markets’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$99.9K Buy
4,052
+45
+1% +$1.04K ﹤0.01% 4376
2025
Q4 		$89.2K Buy
+4,007
New +$70K ﹤0.01% 4425

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BNP Paribas Financial Markets's LBRX Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its LB Pharmaceuticals (LBRX) stake by 1.1% in Q1 2026, buying an estimated $1.04K and bringing the position to 4,052 shares worth $99.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4376.

BNP Paribas Financial Markets first reported a position in LBRX in Q4 2025 and has held it in 2 quarters since. 77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

  • BNP Paribas Financial Markets held 4,052 shares of LB Pharmaceuticals worth $99.9K as of Q1 2026.
  • BNP Paribas Financial Markets bought 45 LB Pharmaceuticals shares in Q1 2026, an estimated $1.04K.
  • LB Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #4376 holding.
  • BNP Paribas Financial Markets first reported a position in LB Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.